Baidu
map

AJG:荟萃分析显示便秘不会增加结直肠癌发病率

2013-07-18 tiancai_erbao dxy

有研究提出长期便秘可能会降低结直肠癌患者的生存率。但其原因尚不清楚,可能与结直肠的解剖结构和病理特征有关。如长期慢性便秘能导致直肠脱垂、痔疮、肛裂以及憩室性疾病等,导致结直肠压力增高及结肠通过时间延长,增加了代谢产物对结直肠粘膜的刺激,而这一现象也是导致结直肠癌发生的原因之一。究竟便秘与结直肠癌之间是否存在相关性呢?英国利兹大学医学院胃肠病学研究所的Andrew M等人对发表日期截止于2012年7

有研究提出长期便秘可能会降低结直肠癌患者的生存率。但其原因尚不清楚,可能与结直肠的解剖结构和病理特征有关。如长期慢性便秘能导致直肠脱垂、痔疮、肛裂以及憩室性疾病等,导致结直肠压力增高及结肠通过时间延长,增加了代谢产物对结直肠粘膜的刺激,而这一现象也是导致结直肠癌发生的原因之一。

究竟便秘与结直肠癌之间是否存在相关性呢?英国利兹大学医学院胃肠病学研究所的Andrew M等人对发表日期截止于2012年7月的研究便秘与结直肠癌相关性的文献进行了系统综述及Meta分析,结果表明便秘与结直肠癌发病率之间并无显著相关性。这一结果发表在2013年6月的The American journal of Gastroenterology上。

作者检索了截止至2012年7月MEDLINE、EMBASE和EMBASE Classic数据库中的文献,筛选以便秘和结直肠癌相关性作为研究对象的横断面研究、队列研究和病例对照研究。对于横断面研究以及队列研究,根据不同便秘状态分别记录实验对象中出现结直肠癌的病例数。病例对照研究,根据结直肠癌患者状态统计存在便秘的病例数。根据公布标准作为研究质量的评估准则。利用随机效应模型将实验数据混合,并利用比值比及95%可信区间总结评估结直肠癌与便秘之间的相关性。

按照检索策略共鉴定了2282篇引文,其中28篇符合要求。在8项横断面研究中发现,因存在便秘而进行结肠镜检查,从而降低了结直肠癌的发病率(OR = 0.56;95% CI 0.36 - 0.89)。在3项队列研究的结果也提示结直肠癌发生呈现低风险趋势(OR = 0.80;95% CI 0.61-1.04)。

17项病例对照研究结果提示在结直肠癌患者中便秘的发生率普遍高于非结直肠癌人群(OR = 1.68;95% CI 1.29-2.18),但入选实验存在显著的异质性且存在发表偏倚。

上述结果中横断面研究及队列研究表明,在存在便秘的患者及个体中,结直肠癌的发病率并无明显上升。在病例对照研究中观察到的两者之间存在相关性的结果可能因回忆偏倚引起。


版权声明:
本网站所有内容来源注明为“梅斯医学”或“MedSci原创”的文字、图片和音视频资料,版权均属于梅斯医学所有。非经授权,任何媒体、网站或个人不得转载,授权转载时须注明来源为“梅斯医学”。其它来源的文章系转载文章,或“梅斯号”自媒体发布的文章,仅系出于传递更多信息之目的,本站仅负责审核内容合规,其内容不代表本站立场,本站不负责内容的准确性和版权。如果存在侵权、或不希望被转载的媒体或个人可与我们联系,我们将立即进行删除处理。
在此留言
评论区 (7)
#插入话题
  1. [GetPortalCommentsPageByObjectIdResponse(id=1823194, encodeId=1490182319447, content=<a href='/topic/show?id=b2873e9220e' target=_blank style='color:#2F92EE;'>#发病率#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=0, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=37922, encryptionId=b2873e9220e, topicName=发病率)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=aa0e14, createdName=lifestar, createdTime=Mon Sep 30 04:08:00 CST 2013, time=2013-09-30, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1681252, encodeId=c5301681252db, content=<a href='/topic/show?id=366b8e2299e' target=_blank style='color:#2F92EE;'>#荟萃#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=57, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=87229, encryptionId=366b8e2299e, topicName=荟萃)], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/aLGWoFXAyMbIu3qymFOyheQLjPSX3OUs5GmkyBlcCOwTPIeq3why9NGibxxUqYo6hcx8qZLHZFgNPnBK1yzWeOFpyg2OnWOt0/0, createdBy=fa4716, createdName=仁心济世, createdTime=Thu Nov 21 11:08:00 CST 2013, time=2013-11-21, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1799777, encodeId=79e61e99777db, content=<a href='/topic/show?id=9e3fe127909' target=_blank style='color:#2F92EE;'>#癌发病#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=57, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=71279, encryptionId=9e3fe127909, topicName=癌发病)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=e2c92500045, createdName=12498636m49(暂无昵称), createdTime=Wed Oct 23 13:08:00 CST 2013, time=2013-10-23, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2079224, encodeId=8b3320e92243f, content=<a href='/topic/show?id=659ce1280ee' target=_blank style='color:#2F92EE;'>#癌发病率#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=73, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=71280, encryptionId=659ce1280ee, topicName=癌发病率)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=1777154, createdName=chenhongpeng, createdTime=Wed Jan 29 12:08:00 CST 2014, time=2014-01-29, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1836842, encodeId=8323183684205, content=<a href='/topic/show?id=1f188e230c5' target=_blank style='color:#2F92EE;'>#荟萃分析#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=0, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=87230, encryptionId=1f188e230c5, topicName=荟萃分析)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=b79433, createdName=fangcong, createdTime=Sun Jan 12 13:08:00 CST 2014, time=2014-01-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2057229, encodeId=c245205e229ca, content=<a href='/topic/show?id=18982222db' target=_blank style='color:#2F92EE;'>#AJG#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=65, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=2222, encryptionId=18982222db, topicName=AJG)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=2978132, createdName=minzju5052, createdTime=Sun Aug 11 21:08:00 CST 2013, time=2013-08-11, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1452634, encodeId=21c1145263486, content=<a href='/topic/show?id=098ee8679ad' target=_blank style='color:#2F92EE;'>#结直肠#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=66, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=78679, encryptionId=098ee8679ad, topicName=结直肠)], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=9ace5575596, createdName=crystal0564, createdTime=Sat Jul 20 02:08:00 CST 2013, time=2013-07-20, status=1, ipAttribution=)]
    2013-09-30 lifestar
  2. [GetPortalCommentsPageByObjectIdResponse(id=1823194, encodeId=1490182319447, content=<a href='/topic/show?id=b2873e9220e' target=_blank style='color:#2F92EE;'>#发病率#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=0, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=37922, encryptionId=b2873e9220e, topicName=发病率)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=aa0e14, createdName=lifestar, createdTime=Mon Sep 30 04:08:00 CST 2013, time=2013-09-30, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1681252, encodeId=c5301681252db, content=<a href='/topic/show?id=366b8e2299e' target=_blank style='color:#2F92EE;'>#荟萃#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=57, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=87229, encryptionId=366b8e2299e, topicName=荟萃)], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/aLGWoFXAyMbIu3qymFOyheQLjPSX3OUs5GmkyBlcCOwTPIeq3why9NGibxxUqYo6hcx8qZLHZFgNPnBK1yzWeOFpyg2OnWOt0/0, createdBy=fa4716, createdName=仁心济世, createdTime=Thu Nov 21 11:08:00 CST 2013, time=2013-11-21, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1799777, encodeId=79e61e99777db, content=<a href='/topic/show?id=9e3fe127909' target=_blank style='color:#2F92EE;'>#癌发病#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=57, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=71279, encryptionId=9e3fe127909, topicName=癌发病)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=e2c92500045, createdName=12498636m49(暂无昵称), createdTime=Wed Oct 23 13:08:00 CST 2013, time=2013-10-23, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2079224, encodeId=8b3320e92243f, content=<a href='/topic/show?id=659ce1280ee' target=_blank style='color:#2F92EE;'>#癌发病率#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=73, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=71280, encryptionId=659ce1280ee, topicName=癌发病率)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=1777154, createdName=chenhongpeng, createdTime=Wed Jan 29 12:08:00 CST 2014, time=2014-01-29, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1836842, encodeId=8323183684205, content=<a href='/topic/show?id=1f188e230c5' target=_blank style='color:#2F92EE;'>#荟萃分析#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=0, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=87230, encryptionId=1f188e230c5, topicName=荟萃分析)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=b79433, createdName=fangcong, createdTime=Sun Jan 12 13:08:00 CST 2014, time=2014-01-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2057229, encodeId=c245205e229ca, content=<a href='/topic/show?id=18982222db' target=_blank style='color:#2F92EE;'>#AJG#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=65, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=2222, encryptionId=18982222db, topicName=AJG)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=2978132, createdName=minzju5052, createdTime=Sun Aug 11 21:08:00 CST 2013, time=2013-08-11, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1452634, encodeId=21c1145263486, content=<a href='/topic/show?id=098ee8679ad' target=_blank style='color:#2F92EE;'>#结直肠#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=66, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=78679, encryptionId=098ee8679ad, topicName=结直肠)], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=9ace5575596, createdName=crystal0564, createdTime=Sat Jul 20 02:08:00 CST 2013, time=2013-07-20, status=1, ipAttribution=)]
  3. [GetPortalCommentsPageByObjectIdResponse(id=1823194, encodeId=1490182319447, content=<a href='/topic/show?id=b2873e9220e' target=_blank style='color:#2F92EE;'>#发病率#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=0, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=37922, encryptionId=b2873e9220e, topicName=发病率)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=aa0e14, createdName=lifestar, createdTime=Mon Sep 30 04:08:00 CST 2013, time=2013-09-30, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1681252, encodeId=c5301681252db, content=<a href='/topic/show?id=366b8e2299e' target=_blank style='color:#2F92EE;'>#荟萃#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=57, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=87229, encryptionId=366b8e2299e, topicName=荟萃)], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/aLGWoFXAyMbIu3qymFOyheQLjPSX3OUs5GmkyBlcCOwTPIeq3why9NGibxxUqYo6hcx8qZLHZFgNPnBK1yzWeOFpyg2OnWOt0/0, createdBy=fa4716, createdName=仁心济世, createdTime=Thu Nov 21 11:08:00 CST 2013, time=2013-11-21, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1799777, encodeId=79e61e99777db, content=<a href='/topic/show?id=9e3fe127909' target=_blank style='color:#2F92EE;'>#癌发病#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=57, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=71279, encryptionId=9e3fe127909, topicName=癌发病)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=e2c92500045, createdName=12498636m49(暂无昵称), createdTime=Wed Oct 23 13:08:00 CST 2013, time=2013-10-23, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2079224, encodeId=8b3320e92243f, content=<a href='/topic/show?id=659ce1280ee' target=_blank style='color:#2F92EE;'>#癌发病率#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=73, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=71280, encryptionId=659ce1280ee, topicName=癌发病率)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=1777154, createdName=chenhongpeng, createdTime=Wed Jan 29 12:08:00 CST 2014, time=2014-01-29, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1836842, encodeId=8323183684205, content=<a href='/topic/show?id=1f188e230c5' target=_blank style='color:#2F92EE;'>#荟萃分析#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=0, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=87230, encryptionId=1f188e230c5, topicName=荟萃分析)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=b79433, createdName=fangcong, createdTime=Sun Jan 12 13:08:00 CST 2014, time=2014-01-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2057229, encodeId=c245205e229ca, content=<a href='/topic/show?id=18982222db' target=_blank style='color:#2F92EE;'>#AJG#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=65, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=2222, encryptionId=18982222db, topicName=AJG)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=2978132, createdName=minzju5052, createdTime=Sun Aug 11 21:08:00 CST 2013, time=2013-08-11, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1452634, encodeId=21c1145263486, content=<a href='/topic/show?id=098ee8679ad' target=_blank style='color:#2F92EE;'>#结直肠#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=66, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=78679, encryptionId=098ee8679ad, topicName=结直肠)], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=9ace5575596, createdName=crystal0564, createdTime=Sat Jul 20 02:08:00 CST 2013, time=2013-07-20, status=1, ipAttribution=)]
  4. [GetPortalCommentsPageByObjectIdResponse(id=1823194, encodeId=1490182319447, content=<a href='/topic/show?id=b2873e9220e' target=_blank style='color:#2F92EE;'>#发病率#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=0, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=37922, encryptionId=b2873e9220e, topicName=发病率)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=aa0e14, createdName=lifestar, createdTime=Mon Sep 30 04:08:00 CST 2013, time=2013-09-30, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1681252, encodeId=c5301681252db, content=<a href='/topic/show?id=366b8e2299e' target=_blank style='color:#2F92EE;'>#荟萃#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=57, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=87229, encryptionId=366b8e2299e, topicName=荟萃)], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/aLGWoFXAyMbIu3qymFOyheQLjPSX3OUs5GmkyBlcCOwTPIeq3why9NGibxxUqYo6hcx8qZLHZFgNPnBK1yzWeOFpyg2OnWOt0/0, createdBy=fa4716, createdName=仁心济世, createdTime=Thu Nov 21 11:08:00 CST 2013, time=2013-11-21, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1799777, encodeId=79e61e99777db, content=<a href='/topic/show?id=9e3fe127909' target=_blank style='color:#2F92EE;'>#癌发病#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=57, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=71279, encryptionId=9e3fe127909, topicName=癌发病)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=e2c92500045, createdName=12498636m49(暂无昵称), createdTime=Wed Oct 23 13:08:00 CST 2013, time=2013-10-23, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2079224, encodeId=8b3320e92243f, content=<a href='/topic/show?id=659ce1280ee' target=_blank style='color:#2F92EE;'>#癌发病率#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=73, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=71280, encryptionId=659ce1280ee, topicName=癌发病率)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=1777154, createdName=chenhongpeng, createdTime=Wed Jan 29 12:08:00 CST 2014, time=2014-01-29, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1836842, encodeId=8323183684205, content=<a href='/topic/show?id=1f188e230c5' target=_blank style='color:#2F92EE;'>#荟萃分析#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=0, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=87230, encryptionId=1f188e230c5, topicName=荟萃分析)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=b79433, createdName=fangcong, createdTime=Sun Jan 12 13:08:00 CST 2014, time=2014-01-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2057229, encodeId=c245205e229ca, content=<a href='/topic/show?id=18982222db' target=_blank style='color:#2F92EE;'>#AJG#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=65, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=2222, encryptionId=18982222db, topicName=AJG)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=2978132, createdName=minzju5052, createdTime=Sun Aug 11 21:08:00 CST 2013, time=2013-08-11, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1452634, encodeId=21c1145263486, content=<a href='/topic/show?id=098ee8679ad' target=_blank style='color:#2F92EE;'>#结直肠#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=66, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=78679, encryptionId=098ee8679ad, topicName=结直肠)], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=9ace5575596, createdName=crystal0564, createdTime=Sat Jul 20 02:08:00 CST 2013, time=2013-07-20, status=1, ipAttribution=)]
  5. [GetPortalCommentsPageByObjectIdResponse(id=1823194, encodeId=1490182319447, content=<a href='/topic/show?id=b2873e9220e' target=_blank style='color:#2F92EE;'>#发病率#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=0, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=37922, encryptionId=b2873e9220e, topicName=发病率)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=aa0e14, createdName=lifestar, createdTime=Mon Sep 30 04:08:00 CST 2013, time=2013-09-30, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1681252, encodeId=c5301681252db, content=<a href='/topic/show?id=366b8e2299e' target=_blank style='color:#2F92EE;'>#荟萃#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=57, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=87229, encryptionId=366b8e2299e, topicName=荟萃)], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/aLGWoFXAyMbIu3qymFOyheQLjPSX3OUs5GmkyBlcCOwTPIeq3why9NGibxxUqYo6hcx8qZLHZFgNPnBK1yzWeOFpyg2OnWOt0/0, createdBy=fa4716, createdName=仁心济世, createdTime=Thu Nov 21 11:08:00 CST 2013, time=2013-11-21, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1799777, encodeId=79e61e99777db, content=<a href='/topic/show?id=9e3fe127909' target=_blank style='color:#2F92EE;'>#癌发病#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=57, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=71279, encryptionId=9e3fe127909, topicName=癌发病)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=e2c92500045, createdName=12498636m49(暂无昵称), createdTime=Wed Oct 23 13:08:00 CST 2013, time=2013-10-23, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2079224, encodeId=8b3320e92243f, content=<a href='/topic/show?id=659ce1280ee' target=_blank style='color:#2F92EE;'>#癌发病率#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=73, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=71280, encryptionId=659ce1280ee, topicName=癌发病率)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=1777154, createdName=chenhongpeng, createdTime=Wed Jan 29 12:08:00 CST 2014, time=2014-01-29, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1836842, encodeId=8323183684205, content=<a href='/topic/show?id=1f188e230c5' target=_blank style='color:#2F92EE;'>#荟萃分析#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=0, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=87230, encryptionId=1f188e230c5, topicName=荟萃分析)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=b79433, createdName=fangcong, createdTime=Sun Jan 12 13:08:00 CST 2014, time=2014-01-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2057229, encodeId=c245205e229ca, content=<a href='/topic/show?id=18982222db' target=_blank style='color:#2F92EE;'>#AJG#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=65, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=2222, encryptionId=18982222db, topicName=AJG)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=2978132, createdName=minzju5052, createdTime=Sun Aug 11 21:08:00 CST 2013, time=2013-08-11, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1452634, encodeId=21c1145263486, content=<a href='/topic/show?id=098ee8679ad' target=_blank style='color:#2F92EE;'>#结直肠#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=66, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=78679, encryptionId=098ee8679ad, topicName=结直肠)], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=9ace5575596, createdName=crystal0564, createdTime=Sat Jul 20 02:08:00 CST 2013, time=2013-07-20, status=1, ipAttribution=)]
  6. [GetPortalCommentsPageByObjectIdResponse(id=1823194, encodeId=1490182319447, content=<a href='/topic/show?id=b2873e9220e' target=_blank style='color:#2F92EE;'>#发病率#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=0, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=37922, encryptionId=b2873e9220e, topicName=发病率)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=aa0e14, createdName=lifestar, createdTime=Mon Sep 30 04:08:00 CST 2013, time=2013-09-30, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1681252, encodeId=c5301681252db, content=<a href='/topic/show?id=366b8e2299e' target=_blank style='color:#2F92EE;'>#荟萃#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=57, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=87229, encryptionId=366b8e2299e, topicName=荟萃)], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/aLGWoFXAyMbIu3qymFOyheQLjPSX3OUs5GmkyBlcCOwTPIeq3why9NGibxxUqYo6hcx8qZLHZFgNPnBK1yzWeOFpyg2OnWOt0/0, createdBy=fa4716, createdName=仁心济世, createdTime=Thu Nov 21 11:08:00 CST 2013, time=2013-11-21, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1799777, encodeId=79e61e99777db, content=<a href='/topic/show?id=9e3fe127909' target=_blank style='color:#2F92EE;'>#癌发病#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=57, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=71279, encryptionId=9e3fe127909, topicName=癌发病)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=e2c92500045, createdName=12498636m49(暂无昵称), createdTime=Wed Oct 23 13:08:00 CST 2013, time=2013-10-23, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2079224, encodeId=8b3320e92243f, content=<a href='/topic/show?id=659ce1280ee' target=_blank style='color:#2F92EE;'>#癌发病率#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=73, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=71280, encryptionId=659ce1280ee, topicName=癌发病率)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=1777154, createdName=chenhongpeng, createdTime=Wed Jan 29 12:08:00 CST 2014, time=2014-01-29, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1836842, encodeId=8323183684205, content=<a href='/topic/show?id=1f188e230c5' target=_blank style='color:#2F92EE;'>#荟萃分析#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=0, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=87230, encryptionId=1f188e230c5, topicName=荟萃分析)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=b79433, createdName=fangcong, createdTime=Sun Jan 12 13:08:00 CST 2014, time=2014-01-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2057229, encodeId=c245205e229ca, content=<a href='/topic/show?id=18982222db' target=_blank style='color:#2F92EE;'>#AJG#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=65, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=2222, encryptionId=18982222db, topicName=AJG)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=2978132, createdName=minzju5052, createdTime=Sun Aug 11 21:08:00 CST 2013, time=2013-08-11, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1452634, encodeId=21c1145263486, content=<a href='/topic/show?id=098ee8679ad' target=_blank style='color:#2F92EE;'>#结直肠#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=66, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=78679, encryptionId=098ee8679ad, topicName=结直肠)], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=9ace5575596, createdName=crystal0564, createdTime=Sat Jul 20 02:08:00 CST 2013, time=2013-07-20, status=1, ipAttribution=)]
    2013-08-11 minzju5052
  7. [GetPortalCommentsPageByObjectIdResponse(id=1823194, encodeId=1490182319447, content=<a href='/topic/show?id=b2873e9220e' target=_blank style='color:#2F92EE;'>#发病率#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=0, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=37922, encryptionId=b2873e9220e, topicName=发病率)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=aa0e14, createdName=lifestar, createdTime=Mon Sep 30 04:08:00 CST 2013, time=2013-09-30, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1681252, encodeId=c5301681252db, content=<a href='/topic/show?id=366b8e2299e' target=_blank style='color:#2F92EE;'>#荟萃#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=57, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=87229, encryptionId=366b8e2299e, topicName=荟萃)], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/aLGWoFXAyMbIu3qymFOyheQLjPSX3OUs5GmkyBlcCOwTPIeq3why9NGibxxUqYo6hcx8qZLHZFgNPnBK1yzWeOFpyg2OnWOt0/0, createdBy=fa4716, createdName=仁心济世, createdTime=Thu Nov 21 11:08:00 CST 2013, time=2013-11-21, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1799777, encodeId=79e61e99777db, content=<a href='/topic/show?id=9e3fe127909' target=_blank style='color:#2F92EE;'>#癌发病#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=57, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=71279, encryptionId=9e3fe127909, topicName=癌发病)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=e2c92500045, createdName=12498636m49(暂无昵称), createdTime=Wed Oct 23 13:08:00 CST 2013, time=2013-10-23, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2079224, encodeId=8b3320e92243f, content=<a href='/topic/show?id=659ce1280ee' target=_blank style='color:#2F92EE;'>#癌发病率#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=73, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=71280, encryptionId=659ce1280ee, topicName=癌发病率)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=1777154, createdName=chenhongpeng, createdTime=Wed Jan 29 12:08:00 CST 2014, time=2014-01-29, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1836842, encodeId=8323183684205, content=<a href='/topic/show?id=1f188e230c5' target=_blank style='color:#2F92EE;'>#荟萃分析#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=0, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=87230, encryptionId=1f188e230c5, topicName=荟萃分析)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=b79433, createdName=fangcong, createdTime=Sun Jan 12 13:08:00 CST 2014, time=2014-01-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2057229, encodeId=c245205e229ca, content=<a href='/topic/show?id=18982222db' target=_blank style='color:#2F92EE;'>#AJG#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=65, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=2222, encryptionId=18982222db, topicName=AJG)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=2978132, createdName=minzju5052, createdTime=Sun Aug 11 21:08:00 CST 2013, time=2013-08-11, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1452634, encodeId=21c1145263486, content=<a href='/topic/show?id=098ee8679ad' target=_blank style='color:#2F92EE;'>#结直肠#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=66, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=78679, encryptionId=098ee8679ad, topicName=结直肠)], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=9ace5575596, createdName=crystal0564, createdTime=Sat Jul 20 02:08:00 CST 2013, time=2013-07-20, status=1, ipAttribution=)]

相关资讯

ASCRS 2013:meta分析显示根治性切除术和局部切除术治疗早期直肠癌疗效基本相当

美国结直肠外科医师协会(ASCRS)2013年会上公布的一项系统综述和meta分析显示,根治性切除术和局部切除术这2种手术治疗方法对早期直肠癌患者的疗效基本相当。 上述结论的依据是涉及2,855例T1N0M0期直肠腺癌患者的13项研究。所有这些研究均发表于1997年之后,当时,全直肠系膜切除和现代局部切除技术已应用于临床。 主要研究者、加拿大西安大略大学外科医生Sami A.&nbs

Ann Surg:术前放化疗不增加直肠癌吻合口瘘风险

在过去十年间,对于术前CRT对AL的影响,相关数据彼此矛盾。对此,韩国延世大学的Woong Sub Koom博士等人进行了一项研究,该研究通过倾向性评分匹配法,评价了在直肠癌切除术前进行的放化疗(CRT)对术后吻合口瘘的影响。这项研究结果发表于2013年4月17日在线出版的《外科学年鉴》(Annals of Surgery)杂志上。最终通过倾向性评分匹配分析发现,术前CRT并未增加接受LAR治疗的

Ann Surg.:PET与CT均不宜预测放化疗前后直肠癌患者缓解情况

直肠癌患者在放化疗后,进行非手术治疗的一个主要干扰就是,无法对术前病理完全缓解进行判定。因此,美国纽约纪念斯隆-凯特琳癌症中心Jose G. Guillem博士等人进行了一项前瞻性研究,在判定经放化疗治疗的直肠癌病理完全缓解(pCR)方面,前瞻性地对氟脱氧葡萄糖正电子放射断层成像技术(FDG-PET)以及计算机断层成像技术(CT)进行对比。这项研究结果于2012年11月26日在线出版的《外科年鉴》

Radiother Oncol:5*5Gy方案和50.4Gy方案治疗不可手术的直肠癌患者无显著差异

在确诊为直肠癌的患者中,大约有15%的患者是无法经由手术切除病变的。对于这部分患者而言,现行的标准治疗方案为先进行6-8周的放化疗,然后再进行手术治疗。放化疗的目的在于让肿瘤缩小以便可以进行根治性切除手术。目前,最常用的治疗方案是放疗总剂量为45Gy或50.4Gy,每次治疗剂量为1.8Gy,化疗的方案为氟尿嘧啶联合甲酰四氢叶酸或卡培他滨。但是即使在应用了上述方案治疗之后,仍有15%的患者的肿瘤仍无

关于印发胃癌等五种恶性肿瘤规范化诊疗指南的通知

关于印发胃癌等五种恶性肿瘤规范化诊疗指南的通知 卫办医管发〔2013〕33号中华人民共和国国家卫生和计划生育委员会     各省、自治区、直辖市卫生厅局(卫生和计划生育委员会),新疆生产建设兵团卫生局:        为进一步推进农村居民重大疾病医疗保障工作,加强恶性肿瘤的规范化诊疗管理,规范诊疗行为,提高诊疗质量,控制诊疗费用,我

DDW 2013:二甲双胍或降低糖尿病患者结直肠癌风险

  奥兰多——在消化疾病周(DDW)上发表的一项Meta分析显示,二甲双胍可能与2型糖尿病患者的结直肠癌(CRC)风险降低有关。   罗切斯特梅奥医院的Siddharth Singh医生报告称,磺酰脲类和胰岛素均与CRC风险降低无关,反而显示出风险增加的不显著趋势。未观察到CRC与噻唑烷二酮(TZD)类药物之间有关。   糖尿病是明确的CRC危险因素,而且临床前和观察性研究已显示,抗糖尿病药物

Baidu
map
Baidu
map
Baidu
map